The year ahead in diabetes care: what to expect in 2023

[Image courtesy of Walmart] After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023.

Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more.

You can read all about the biggest diabetes stories of 2022 here.

As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.

CMS decision could benefit CGMs

In October, The Centers for Medicare and Medicaid Services (CMS) published a new local coverage determination (LCD). That LCD modified coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.

Analysts suggested at the time that the decision marked a win for …

Read more
  • 0

Amalgam Rx, Novo Nordisk expand partnership on connected insulin delivery devices

[Image courtesy of Amalgam Rx/Novo Nordisk]Amalgam Rx announced today that it expanded its global agreement with Novo Nordisk over the commercialization of Dose Check.

Wilmington, Delaware-based Amalgam Rx develops the Dose Check digital insulin initiation and titration app. It designed the app to help people with type 2 diabetes using basal insulin.

The two companies partnered to incorporate and integrate connected insulin delivery devices, continuous glucose monitors and electronic health records. Novo Nordisk also intends to make an equity investment in Amalgam.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Abbott FreeStyle LibreLink app now pairs with Novo Nordisk insulin pens in UK

The NovoPen Echo smart insulin pen. [Image from Novo Nordisk]Novo Nordisk (NYSE:NVO) announced that users of the Abbott (NYSE:ABT) FreeStyle LibreLink app can connect to its smart insulin pens.

People living with diabetes in the United Kingdom can connect the app to the Novo Nordisk smart, connected pens. Users of the Abbott FreeStyle LibreLink app with FreeStyle Libre glucose sensing technology can see a range of information related to their diabetes. This includes dose timing and the amount of insulin taken, plus how those metrics impact their individual glucose patterns.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

WHO delivers insulin pens to Ukraine hospitals with support from Novo Nordisk

[Image from WHO]The World Health Organization (WHO) announced that it delivered more than 26 metric tonnes of insulin pens to Ukraine.

WHO distributed approximately 57,320 pounds of insulin pens (more than 370,000 total pens) to hospitals throughout Ukraine. It represents part of an effort to help those with diabetes in the country during the ongoing humanitarian crisis.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

10 leading pharma executives you need to know

Pfizer CEO Dr. Albert Bourla [Image courtesy of Pfizer/Business Roundtable]Given the complexity of the pharmaceutical business, it can be challenging to gauge the performance of any chief executive in the space.

That said, CEOs’ annualized return over tenure as CEO over their term can hint at performance. In addition, rating sites like Glassdoor also indicate CEOs’ popularity.

Here, we parsed a range of metrics, including CEOs’ approval ratings, their ability to navigate the pandemic and their firms’ stock performance over time, to identify ten leading pharma executives.

Get the full story from our sister site, Drug Discovery & Development. 

Read more
  • 0

Novo Nordisk completes acquisition of Dicerna Pharmaceuticals

Novo Nordisk (NYSE:NVO) announced today that its acquisition of Dicerna Pharmaceuticals (NSDQ:DRNA) has been completed.

Completion of the acquisition, initially announced on Nov. 18, 2021, follows the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna at 11:59 p.m. ET on Dec. 24, 2021.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Waiting period for Novo Nordisk’s proposed acquisition of Dicerna expires

Dicerna Pharmaceuticals (NSDQ:DRNA) announced that a waiting period for a proposed acquisition by Novo Nordisk (NYSE:NVO) has expired.

The announcement, made on Dec. 25, confirmed that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) in connected on with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m. ET on Dec. 24, 2021.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes

The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms.

In an effort to accelerate efforts to mine genetic data for insights into mechanisms, and eventually rationally designed treatments, the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based at the Broad Institute in Cambridge, Massachusetts.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Walmart teams up with Novo Nordisk to launch private-brand analog insulin 

Walmart (NYSE:WMT) is launching what it describes as the first private label analog insulin. The company estimates the insulin products will save customers between 58% and 70% of the cost of branded insulin.

Novo Nordisk (NYSE:NVO) will manufacture the analog insulin, which is a type of lab-grown insulin genetically engineered to optimize glucose control. The retail price of analog insulin vials will be $72.88, while a FlexPen insulin pen will cost $85.88. Walmart has concluded that the per-unit savings of the products will be $101 per vial and $251 per insulin pen, respectively.

The insulin will only be available through Walmart’s ReliOn brand of diabetes products.

Get the full story from our sister site, Drug Delivery Business.

Read more
  • 0

Bigfoot Biomedical wins FDA clearance for smart insulin pen cap system

[Image from Bigfoot Biomedical]Bigfoot Biomedical announced today that it received FDA 510(k) clearance for its Bigfoot Unity diabetes management system.

Milpitas, Calif.-based Bigfoot’s first-of-its-kind Bigfoot Unity system features connected smart pen caps designed to recommend insulin doses for diabetes patients using multiple daily injection (MDI) therapy, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Once-a-week insulin dosing shows promise in studies

[Image from Mykenzie Johnson on Unsplash]Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes.

Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Once-a-week insulin dosing shows promise in studies

[Image from Mykenzie Johnson on Unsplash]Studies suggest that a new once-per-week injectable insulin therapy is safe and as effective as daily injections for those with type 2 diabetes.

Two international clinical trials published today in Diabetes Care found that the once-weekly treatment has the potential to offer a convenient alternative to daily insulin shots for those with type 2 diabetes, according to a news release.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0